ReviewExpert opinion on biological therapy2008
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Review in Expert opinion on biological therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02698280 (Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma), which is not on this map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Who cites it
33 citing papers in PubMed, 85 citations in OpenAlex.
- Salvage therapy with single agent bendamustine for recurrent glioblastoma.Journal of neuro-oncology · 2011Trial
- Salvage therapy with single agent bevacizumab for recurrent glioblastoma.Journal of neuro-oncology · 2010Trial
- Review
- The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence also in Comparison with MRI.Diagnostics (Basel, Switzerland) · 2022Review
- Article
- Present and Future of Anti-Glioblastoma Therapies: A Deep Look into Molecular Dependencies/Features.Molecules (Basel, Switzerland) · 2020Review
- Imaging signatures of glioblastoma molecular characteristics: A radiogenomics review.Journal of magnetic resonance imaging : JMRI · 2020Review
- Response Assessment in Neuro-Oncology Criteria for Gliomas: Practical Approach Using Conventional and Advanced Techniques.AJNR. American journal of neuroradiology · 2020Review
- Review
- RUNX1 Regulates Migration, Invasion, and Angiogenesis via p38 MAPK Pathway in Human Glioblastoma.Cellular and molecular neurobiology · 2017Article
- Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.Frontiers in cellular neuroscience · 2017Review
- Treatment of adult and pediatric high-grade gliomas with Withaferin A: antitumor mechanisms and future perspectives.Journal of natural medicines · 2017Review
- Radiologic Features and Expression of Vascular Endothelial Growth Factor Stratify Survival Outcomes in Patients with Glioblastoma.AJNR. American journal of neuroradiology · 2016Article
- Glioblastoma Stem Cells Microenvironment: The Paracrine Roles of the Niche in Drug and Radioresistance.Stem cells international · 2016Review
- The Dynamics of Interactions Among Immune and Glioblastoma Cells.Neuromolecular medicine · 2015Review
- The Cancer Genome Atlas Analysis Predicts MicroRNA for Targeting Cancer Growth and Vascularization in Glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters · 2015Article
- Nitroxoline induces apoptosis and slows glioma growth in vivo.Neuro-oncology · 2015Article
- VEGF₁₂₁-conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system.ACS applied materials & interfaces · 2014Article
- Bevacizumab for glioblastoma-a promising drug or not?Cancers · 2013Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundAdults with malignant glioma, especially the most common subtype, glioblastoma multiforme, have an unacceptably poor outcome with current therapies. Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors.
objectiveTo summarize the clinical experience of VEGF-directed treatment for malignant glioma.
methodsWe reviewed the completed, ongoing and planned clinical trials evaluating anti-VEGF strategies for malignant glioma patients. RESULTS/
conclusionsRecent studies incorporating anti-VEGF agents plus cytotoxic therapy among recurrent malignant glioma patients have achieved unprecedented improvements in radiographic response, time to progression and survival. Furthermore, acceptable toxicity was observed. Hence, a major current focus in neuro-oncology is to further develop antiangiogenic strategies for this desperate patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.